ATE342054T1 - Verfahren und zusammansetzung zur behandlung von krebs - Google Patents

Verfahren und zusammansetzung zur behandlung von krebs

Info

Publication number: ATE342054T1
Authority: AT; Austria
Prior art keywords: composition; lapachone; beta; administration; treating cancer
Prior art date: 1999-04-14

Application number

AT00922237T

Other languages

English (en)

Inventor

Arthur B Pardee

Chiang J Li

You-Zhi Li

Original Assignee

Dana Farber Cancer Inst Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-14

Filing date

2000-04-14

Publication date

2006-11-15

2000-04-14 Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE342054T1 publication Critical patent/ATE342054T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title 1
QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 abstract 4
229930012538 Paclitaxel Natural products 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229960001592 paclitaxel Drugs 0.000 abstract 2
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
230000010190 G1 phase Effects 0.000 abstract 1
230000018199 S phase Effects 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
231100000161 signs of toxicity Toxicity 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)

AT00922237T 1999-04-14 2000-04-14 Verfahren und zusammansetzung zur behandlung von krebs ATE342054T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12926199P	1999-04-14	1999-04-14

Publications (1)

Publication Number	Publication Date
ATE342054T1 true ATE342054T1 (de)	2006-11-15

Family

ID=22439161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00922237T ATE342054T1 (de)	1999-04-14	2000-04-14	Verfahren und zusammansetzung zur behandlung von krebs

Country Status (8)

Country	Link
US (3)	US6664288B1 (de)
EP (1)	EP1181013B1 (de)
JP (2)	JP2002541200A (de)
AT (1)	ATE342054T1 (de)
CA (1)	CA2369303A1 (de)
DE (1)	DE60031268T2 (de)
ES (1)	ES2273688T3 (de)
WO (1)	WO2000061142A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US6242469B1 (en) *	1996-12-03	2001-06-05	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US7820718B1 (en) *	1999-04-07	2010-10-26	Roger Williams Hospital	Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
US6664288B1 (en) *	1999-04-14	2003-12-16	Dana Farber Cancer Institute, Inc.	Method and composition for the treatment of cancer
US20050192360A1 (en) *	1999-04-14	2005-09-01	Li Chiang J.	Method of treatment of pancreatic cancer
US20050222246A1 (en) *	1999-04-14	2005-10-06	Li Chiang J	Beta-lapachone is a broad spectrum anti-cancer agent
HK1052870A1 (zh) *	2000-10-05	2003-10-03	Q. Daley George	诱导癌细胞死亡和肿瘤消退的方法
US6822001B2 (en)	2000-11-03	2004-11-23	Tularik Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) *	2000-11-03	2005-11-10	Amgen Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050197405A1 (en) *	2000-11-07	2005-09-08	Li Chiang J.	Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
JP4244141B2 (ja) *	2000-11-07	2009-03-25	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	血液腫瘍および血液癌を処置する方法
US7070797B2 (en)	2000-11-07	2006-07-04	Dana Farber Cancer Institute, Inc.	Method of treating hematologic tumors and cancers
US20020183266A1 (en) *	2001-03-15	2002-12-05	Aventis Pharma, S.A.	Combination comprising combretastatin and anticancer agents
US6756063B2 (en) *	2001-03-29	2004-06-29	Zoltan Laboratories, Llc	Methods and compositions for the treatment of human and animal cancers
US20030212147A1 (en) *	2001-07-12	2003-11-13	Chung Sum Man Stephen	Enzyme activated chemotherapy of liver cancer
US7074824B2 (en)	2001-07-31	2006-07-11	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en)	2001-07-31	2005-11-08	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
US20030220376A1 (en) *	2001-08-10	2003-11-27	Pharmacia Corporation	Methods for treating carbonic anhydrase mediated disorders
US20040067992A1 (en) *	2001-08-10	2004-04-08	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) *	2001-08-10	2003-05-29	Pharmacia Corporation	Carbonic anhydrase inhibitor
AU2007200677B2 (en) *	2002-01-14	2009-10-29	Novartis Ag	Combinations comprising epothilones and anti-metabolites
RU2346686C2 (ru) *	2002-01-14	2009-02-20	Новартис Аг	Комбинации, включающие эпотилоны и антиметаболиты
US6816571B2 (en) *	2002-02-06	2004-11-09	L-3 Communications Security And Detection Systems Corporation Delaware	Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US6890950B2 (en)	2002-04-23	2005-05-10	Case Western Reserve University	Lapachone delivery systems, compositions and uses related thereto
WO2004103267A2 (en) *	2002-05-20	2004-12-02	Kosan Biosciences, Inc.	Methods to administer epothilone d
CA2492772A1 (en) *	2002-07-17	2004-01-22	Chiang J. Li	Activated checkpoint therapy and methods of use thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en)	2002-08-23	2004-03-04	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2006504745A (ja) *	2002-10-09	2006-02-09	コーザンバイオサイエンシスインコーポレイテッド	エポｄ及び５−ｆｕ／ゲムシタビン
JP2006508147A (ja) *	2002-11-18	2006-03-09	アルキュール，インコーポレイテッド	新規ラパコン化合物およびその使用方法
AU2003293333A1 (en) *	2002-12-02	2004-06-23	Arqule, Inc.	Method of treating cancers
US7670627B2 (en) *	2002-12-09	2010-03-02	Salvona Ip Llc	pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CA2546622A1 (en) *	2003-11-26	2005-06-09	Amadeo Parissenti	Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment
JP2007512378A (ja)	2003-11-26	2007-05-17	アークルインコーポレイテッド	放射線障害から保護するためのβ−ラパコンの使用
EP1722777A2 (de) *	2004-02-20	2006-11-22	Arqule, Inc.	Verwendung von beta-lapachone zur behandlung von pangreaskarzinomen
CA2555941A1 (en) *	2004-02-20	2005-09-09	Arqule, Inc.	Use of beta-lapachone for treatment of colon cancer
US20050187288A1 (en) *	2004-02-20	2005-08-25	Chiang Li	Beta-lapachone and methods of treating cancer
EP1729760A2 (de) *	2004-02-20	2006-12-13	Arqule, Inc.	Verwendung von beta-lapachon zur behandlung von lungenkrebs
US20050192247A1 (en) *	2004-02-23	2005-09-01	Li Chiang J.	Method of treating cancers
US20040224019A1 (en) *	2004-03-03	2004-11-11	Adi Shefer	Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US8415315B2 (en)	2004-05-06	2013-04-09	University Of Central Florida Research Foundation, Inc.	Methods and compositions for inhibiting the proliferation of cancer cells
CA2583700A1 (en)	2004-08-11	2006-02-23	Arqule, Inc.	Quinone prodrug compositions and methods of use
US8614228B2 (en)	2004-08-11	2013-12-24	Arqule, Inc.	Quinone prodrug compositions and methods of use
DE102005055385A1 (de) *	2004-12-09	2006-06-14	Bayer Healthcare Ag	Arzneimittel zur hygienischen Applikation im Ohr
WO2006078503A2 (en)	2005-01-07	2006-07-27	Arqule, Inc.	Compositions for modulation of parp and methods for screening for same
CN101415420B (zh) *	2006-04-05	2012-09-05	诺瓦提斯公司	用于治疗癌症的治疗剂的组合
WO2007139569A1 (en) *	2006-05-26	2007-12-06	Arqule, Inc.	Novel lapachone compounds and methods of use thereof
TW200824692A (en)	2006-08-21	2008-06-16	Arqule Inc	Novel lapachone compounds and methods of use thereof
US7790765B2 (en)	2007-04-30	2010-09-07	Arqule, Inc.	Hydroxy sulfonate of quinone compounds and their uses
US8067459B2 (en)	2007-10-16	2011-11-29	Arqule, Inc.	Lapachone compounds and methods of use thereof
US7808078B2 (en) *	2008-08-26	2010-10-05	Sanyo Electric Co., Ltd.	Semiconductor device and manufacturing method thereof
US8658170B2 (en) *	2010-01-06	2014-02-25	Joseph P. Errico	Combination therapy with MDM2 and EFGR inhibitors
EP2521553A4 (de)	2010-01-06	2013-08-28	Errico Joseph P	Verfahren und zusammensetzungen für gezielte wirkstoffentwicklung
PT2619331T (pt)	2010-09-22	2018-06-01	Univ Texas	Métodos de tratamento de cancro incluindo rastreio de nqo1
WO2012162627A1 (en) *	2011-05-26	2012-11-29	The General Hospital Corporation	Treatment of angiogenic- or vascular-associated diseases
BRPI1106509A2 (pt) *	2011-10-25	2013-11-19	Universidade Federal Do Rio De Janeiro Ufrj	Uso das pironofatoquinona como antiviral; composição farmacêutica contendo as piranonaftoquinonas; medicamento contendo as piranonaftoquinonas para tratamento de infecções causadas por virus da dengue
CN104971351A (zh) *	2014-04-08	2015-10-14	清华大学	药物组合物及其应用
WO2017015301A1 (en)	2015-07-20	2017-01-26	Rutgers, The State University Of New Jersey	Ceramide derivatives as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5763625A (en) *	1995-04-25	1998-06-09	Wisconsin Alumni Research Foundation	Synthesis and use of β-lapachone analogs
US6664288B1 (en) *	1999-04-14	2003-12-16	Dana Farber Cancer Institute, Inc.	Method and composition for the treatment of cancer

2000
- 2000-04-14 US US09/958,479 patent/US6664288B1/en not_active Expired - Fee Related
- 2000-04-14 ES ES00922237T patent/ES2273688T3/es not_active Expired - Lifetime
- 2000-04-14 AT AT00922237T patent/ATE342054T1/de not_active IP Right Cessation
- 2000-04-14 DE DE60031268T patent/DE60031268T2/de not_active Expired - Fee Related
- 2000-04-14 WO PCT/US2000/010169 patent/WO2000061142A1/en not_active Ceased
- 2000-04-14 JP JP2000610475A patent/JP2002541200A/ja active Pending
- 2000-04-14 CA CA002369303A patent/CA2369303A1/en not_active Abandoned
- 2000-04-14 EP EP00922237A patent/EP1181013B1/de not_active Expired - Lifetime
2003
- 2003-10-09 US US10/683,199 patent/US6875745B2/en not_active Expired - Fee Related
2005
- 2005-03-01 US US11/069,637 patent/US20050171031A1/en not_active Abandoned
2008
- 2008-09-01 JP JP2008224161A patent/JP2009051841A/ja active Pending

Also Published As

Publication number	Publication date
US20050171031A1 (en)	2005-08-04
CA2369303A1 (en)	2000-10-19
JP2009051841A (ja)	2009-03-12
EP1181013B1 (de)	2006-10-11
US6664288B1 (en)	2003-12-16
WO2000061142A1 (en)	2000-10-19
DE60031268D1 (de)	2006-11-23
US6875745B2 (en)	2005-04-05
EP1181013A1 (de)	2002-02-27
US20040087610A1 (en)	2004-05-06
EP1181013A4 (de)	2004-07-07
DE60031268T2 (de)	2007-05-24
ES2273688T3 (es)	2007-05-16
JP2002541200A (ja)	2002-12-03

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
EP1181013A4 (de)	2004-07-07	Verfahren und zusammansetzung zur behandlung von krebs
ATE310506T1 (de)	2005-12-15	Biodegradierbare polyphosphoester- zusammensetzungen zur behandlung von ovarialkrebs
RU94029662A (ru)	1996-07-10	Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE421322T1 (de)	2009-02-15	Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
GB0305152D0 (en)	2003-04-09	Organic compounds
EP1622608A4 (de)	2010-11-10	Zusammensetzungen und verfahren zur behandlung von krebs
GEP20043322B (en)	2003-12-10	C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
ATE322265T1 (de)	2006-04-15	Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2002058694A3 (en)	2003-12-04	Method of treating hematologic tumors and cancers using beta lapachone
ATE260282T1 (de)	2004-03-15	Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DK1056704T3 (da)	2003-08-18	Antitumormidler
TW200510367A (en)	2005-03-16	Novel lapachone compounds, their preparation, and the use thereof
DE60334711D1 (de)	2010-12-09	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
EA200600992A1 (ru)	2006-10-27	Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
DE69815100D1 (de)	2003-07-03	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
ATE393624T1 (de)	2008-05-15	Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE359800T1 (de)	2007-05-15	Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
BRPI0410026A (pt)	2006-04-25	derivados de 3-amino-croman quinolina
MXPA02010813A (es)	2004-02-26	Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.
WO2005102997A8 (en)	2006-11-23	3,4-disubstituted maleimides for use as vascular damaging agents
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004014125D1 (de)	2008-07-10	Ruthenium(ii)-komplexe zur behandlung von tumoren
DE60305520D1 (de)	2006-06-29	2" oxo-voruscharin und derivaten
HK1154859A1 (zh)	2012-05-04	用於治療癌症的異吲哚啉化合物